Navigation Links
ResMed Announces Acquisition of BiancaMed
Date:7/6/2011

SAN DIEGO, July 6, 2011 /PRNewswire/ -- ResMed Inc. (NYSE: RMD and ASX: RMD), a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders, announced today that it has acquired BiancaMed Ltd., a leading Irish medical technology company.  ResMed purchased all of BiancaMed's outstanding shares with cash.  

(Logo:  http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

BiancaMed has developed and is marketing an innovative, convenient, non-contact device to monitor sleep and breathing in the home and hospital.  BiancaMed's SleepMinder™ is an accurate, touch-free device that measures sleep and breathing with sophisticated biometric software. The core of BiancaMed's proprietary technology is a motion sensor that can detect respiration and movement without physical contact with the human body.  The company is developing a number of other applications for the technology, across a range of medical and consumer settings.   BiancaMed will become a part of ResMed's newly-created Ventures and Initiatives unit.  ResMed estimates the acquisition will dilute ResMed's earnings per share by approximately $0.04 in fiscal year 2012, excluding amortization of intangibles and one-time acquisition related costs.

"We are committed to innovation in sleep and respiratory medicine and the related co-morbidities by commercializing products incorporating novel technologies," commented Dr. Peter Farrell, ResMed's chairman and chief executive officer. "We have worked closely with BiancaMed for many years and have been investors since their inception in 2003. BiancaMed has exciting technology and a world-class team. We believe there are many opportunities for BiancaMed's applications that will provide future growth, and we look forward to maintaining and building the BiancaMed team."

Welcoming this announcement, Dr. Conor Hanley, BiancaMed's chief executive officer, said, "This acquisition will broaden the use of BiancaMed's unique technology and build on BiancaMed's momentum. As part of ResMed, we will continue to support our existing customers. The successful completion of this transaction was attributable to the dedication and talent of the BiancaMed team and the invaluable support received from all our investors and shareholders."

JC Kyrillos, president of ResMed Ventures and Initiatives, stated, "In May of this year, we created ResMed Ventures and Initiatives to focus on opportunities in chronic disease states related to sleep-disordered breathing and other market opportunities.  BiancaMed represents the type of investment we are pursuing because it has current applications in our core sleep market, and several potential future applications in chronic diseases such as heart failure and chronic obstructive pulmonary disease."    

BiancaMed, a University College Dublin spin-out company, was co-founded in 2003 by Dr. Philip de Chazal, Dr. Conor Hanley and Professor Conor Heneghan to commercialize research undertaken in University College Dublin's School of Electrical, Electronic and Mechanical Engineering. BiancaMed is headquartered in NovaUCD, the Innovation and Technology Transfer Centre, and currently employs 29 people. ResMed plans to retain BiancaMed's employees, and the office in Dublin will remain active.

Further information can be obtained by visiting the company's multilingual website at www.resmed.com.  For more information on BiancaMed, visit:  www.biancamed.com.

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission.  Those reports are available on the Company's Web site.


'/>"/>
SOURCE ResMed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ResMed Announces New iPhone App
2. ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011
3. The Next Generation in Bilevel Therapy Now Available on ResMeds Award-Winning S9™ Platform
4. ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results
5. ResMed Inc. Announces Management Changes
6. ResMed Inc. Announces Record Financial Results for the Quarter Ended and Six Months Ended December 31, 2010
7. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results
8. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010
9. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results
10. Study Shows ResMeds New CPAP Device Increases Patient Compliance
11. ResMed Inc. Announces Completion of Two-for-One Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb.8, 2016 Alzheimer Diagnostic Tests - ... Medical Devices sector report , "Alzheimer Diagnostic ... an overview of Alzheimer Diagnostic Tests currently in ... on the pipeline products with comparative analysis of ... report reviews major players involved in the pipeline ...
(Date:2/8/2016)... 2016 Cardiovascular Surgery Devices - Medical ... Medical Devices sector report, "Cardiovascular Surgery Devices - ... of Cardiovascular Surgery Devices currently in pipeline stage. ... The report provides comprehensive information on the pipeline ... various stages of development. The report reviews major ...
(Date:2/8/2016)... NEW YORK , Feb. 8, 2016 /PRNewswire/ ... market, today announces its first male sexual enhancement ... enhancement, EnduramenT combines proven ethnobotanicals with a patented ... of nitric oxide, the chemical compound responsible for ... Forgoing the ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
(Date:2/8/2016)... Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired ... also was the American Cancer Society’s 2015 CEO of the Year , helped ...
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):